# Ruben Osnabrugge

> Ruben Osnabrugge is a Series B investor at 415 Capital backing Medical and Medical Device. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [415 Capital](https://shizune.co/investors/profile/415-capital-management)
- Total investments: 2
- Last investment: Apr 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/rubenosnabrugge

Ruben Osnabrugge is a Series B investor at 415 Capital focused on Medical and Medical Device. Ruben Osnabrugge

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Medical Device | 1 | 50% |
| Clinical Trials | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series C | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Endovascular Engineering | Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $80M | Series C | Apr 07, 2026 |  |
| Endovascular Engineering | Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $42M | Series B | Feb 18, 2025 |  |

2 of 2 investments shown.

## Co-investors
- [M&L Healthcare Investments](https://shizune.co/investors/profile/m-l-healthcare-investments) — VC Fund, 2 deals together
- [Panakes Partners](https://shizune.co/investors/profile/panakes-partners) — VC Fund, 2 deals together
- [S3 Ventures](https://shizune.co/investors/profile/s3-ventures) — VC Fund, 2 deals together
- [Sante Ventures](https://shizune.co/investors/profile/sante-ventures) — VC Fund, 2 deals together
- [Cordis](https://shizune.co/investors/profile/cordis) — VC Fund, 1 deal together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 1 deal together

## About 415 Capital

VC Fund · Oberhaching, Germany

415 CAPITAL is a specialist venture capital firm that invests in early- and development-stage MedTech companies in Europe, the United States and Israel.They primarily invest in innovative medical device technologies addressing cardiovascular disease: the worldwide leading cause of death and the single largest cost driver in the global healthcaresystem.We are investors AND entrepreneurs: As investors, They have funded 45 MedTech companies in the past 28 years. As entrepreneurs, They have founded, built, and exited several successful European MedTech distribution companies.

4 contacts available at 415 Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Azin Parhizgar | Senior Venture Partner | https://shizune.co/investors/profile/azin-parhizgar |
| Frank Groenewegen | Managing Director | https://shizune.co/investors/profile/frank-groenewegen |
| Frederik Groenewegen | Managing Director | https://shizune.co/investors/profile/frederik-groenewegen |
| Ruben Osnabrugge | Partner | https://shizune.co/investors/profile/ruben-osnabrugge-75e5 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ruben Osnabrugge invest in?

Ruben Osnabrugge invests primarily in Medical, Medical Device and Clinical Trials startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ruben Osnabrugge last invest?

The most recent investment recorded for Ruben Osnabrugge closed in Apr 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co